Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001
Pharmacokinetics of oral voriconazole in adults with cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010
Once-daily tobramycin in the treatment of adult patients with cystic fibrosis Source: Eur Respir J 2002; 19: 303-309 Year: 2002
Home intravenous antibiotic treatments in cystic fibrosis adult patients Source: Eur Respir J 2002; 20: Suppl. 38, 158s Year: 2002
Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005
Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005
A UK experience of temocillin in the treatment of adult cystic fibrosis patients Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Safety and efficacy of intravenous (IV) Fosfomycin in adult cystic fibrosis patients Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018
The prevalence and characteristics of intravenous (IV) antibiotics allergy in adult patient with cystic fibrosis (CF) Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012
An anti-inflammatory effect of azithromycin in cystic fibrosis Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010
Daily versus weekly azithromycin in cystic fibrosis patients Source: Eur Respir J 2007; 30: 487-495 Year: 2007
Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012
Effect of home intravenous antibiotic treatment on exercise capacity in children with cystic fibrosis Source: Annual Congress 2010 - Gas exchange and paediatric exercise testing Year: 2010
Inhaled antibiotics in non-cystic fibrosis bronchiectasis: better than oral antibiotics? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Usefulness of long term treatment with azithromycin in patients with bronchiectasis (non cystic fibrosis) Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002
Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003
Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014
Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020